Janux Therapeutics (NASDAQ:JANX) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Monday morning, Benzinga reports. The firm currently has a $100.00 price objective on the stock.

A number of other equities research analysts have also issued reports on JANX. Wedbush reiterated an outperform rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. HC Wainwright reiterated a buy rating and set a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. Stifel Nicolaus assumed coverage on Janux Therapeutics in a research note on Friday, September 6th. They set a buy rating and a $70.00 price objective for the company. Finally, Scotiabank dropped their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a sector perform rating for the company in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $66.13.

Janux Therapeutics Stock Performance

JANX opened at $49.98 on Monday. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $65.60. The firm has a 50 day moving average price of $43.28 and a 200 day moving average price of $44.19. The company has a market cap of $2.59 billion, a PE ratio of -40.97 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. The business’s revenue was up 709.1% compared to the same quarter last year. On average, sell-side analysts predict that Janux Therapeutics will post -1.18 earnings per share for the current year.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 268,578 shares of company stock worth $12,071,151 in the last 90 days. Corporate insiders own 35.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capstone Investment Advisors LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at approximately $1,969,000. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Janux Therapeutics in the 1st quarter valued at $739,000. Virtu Financial LLC bought a new position in Janux Therapeutics during the first quarter valued at about $609,000. Finally, Vanguard Group Inc. lifted its position in shares of Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.